pubmed.ncbi.nlm.nih.gov

Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates - PubMed

Review

Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates

Dan Ye et al. Trends Cancer. 2018 Feb.

Abstract

Isocitrate dehydrogenases (IDH1/2) are frequently mutated in multiple types of human cancer, resulting in neomorphic enzymes that convert α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG). The current view on the mechanism of IDH mutation holds that 2-HG acts as an antagonist of α-KG to competitively inhibit the activity of α-KG-dependent dioxygenases, including those involved in histone and DNA demethylation. Recent studies have implicated 2-HG in activities beyond epigenetic modification. Multiple enzymes have been discovered that lack mutations but that can nevertheless produce 2-HG promiscuously under hypoxic or acidic conditions. Therapies are being developed to treat IDH-mutant cancers by targeting either the mutant IDH enzymes directly or the pathways sensitized by 2-HG.

Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Metabolism and Targets of 2-Hydroxyglutarate (2-HG)

The thick and thin arrows represent the primary and promiscuous reactions, respectively. FAD, flavin adenine dinucleotide; FADH2, reduced form of FAD; NADP, nicotinamide adenine dinucleotide phosphate; NADPH, reduced form of NADP. Additional abbreviations are listed in Table 1.

Figure 2
Figure 2. Production of 2-Hydroxyglutarate (2-HG) by Promiscuous Enzymatic Reactions

The thick and thin arrows represent the primary and promiscuous reactions, respectively. PHDGH, phosphoglycerate dehydrogenase; 3PG, 3-phosphoglycerate; 3PHP, 3-phosphohydroxypyruvate. Additional abbreviations are listed in Figure 1.

Similar articles

Cited by

References

    1. Parsons DW, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–1812. - PMC - PubMed
    1. Mardis ER, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058–1066. - PMC - PubMed
    1. Yang H, et al. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res. 2012;18:5562–5571. - PMC - PubMed
    1. Dang L, Su SM. Isocitrate dehydrogenase mutation and (R)-2-hydroxyglutarate: from basic discovery to therapeutics development. Annu Rev Biochem. 2017;86:305–331. - PubMed
    1. Watanabe T, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174:1149–1153. - PMC - PubMed

Publication types

MeSH terms

Substances